DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
GSK2636771 is an investigational drug.
There have been 7 clinical trials for GSK2636771. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2015.
The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), GlaxoSmithKline, and M.D. Anderson Cancer Center.
There are twelve US patents protecting this investigational drug and seventy-six international patents.
Recent Clinical Trials for GSK2636771
|Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss||GlaxoSmithKline||Phase 1/Phase 2|
|Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss||Merck Sharp & Dohme Corp.||Phase 1/Phase 2|
|Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for GSK2636771
Top clinical trial sponsors for GSK2636771
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GSK2636771||Start Trial||Benzimidazole derivatives as PI3 kinase inhibitors||GlaxoSmithKline LLC (Wilmington, DE)||Start Trial|
|GSK2636771||Start Trial||Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof||RACE ONCOLOGY LTD. (Melbourne, AU)||Start Trial|
|GSK2636771||Start Trial||Benzimidazole derivatives as P13 kinase inhibitors||GlaxoSmithKline LLC (Philadelphia, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|